Cite
HARVARD Citation
Vey, N. et al. (2017). Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia. Leukemia & lymphoma. 58 (8), pp. 1880-1886. [Online].